Pharma Journalist -

Read More...

Everest Medicines Limited announced today two separate definitive agreements with Providence Therapeutics Holdings Inc., a clinical stage biotechnology company developing messenger RNA…
Read More...

AbbVie and REGENXBIO Inc. announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet…
Read More...

Cytiva, a global life sciences leader, continues to expand its manufacturing capacity for bioprocessing single-use consumables in China. In collaboration with Wego Pharmaceutical Co.…
Read More...

Twist Bioscience Corporation a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced a broad-based research…
Read More...

GeneQuine Biotherapeutics GmbH, a biotech company focused on the development of gene therapy for musculoskeletal disorders, announced that it has contracted Exothera S.A., a…
Read More...

The Phase 3 PEGASUS trial evaluating rilzabrutinib to treat pemphigus, a rare autoimmune skin condition, did not meet its primary or key secondary endpoints. Rilzabrutinib’s safety…
Read More...

Repligen Corporation a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH (“Navigo”), announced they have completed development and…
Read More...

Humanigen, Inc. a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced the U.S. FDA has declined its…
Read More...

Frontage Shanghai announced the acquisition of 70% equity interest in Wuhan Heyan Biomedical Technology Co., Ltd. ("Heyan Biotech") Heyan Biotech, located in Wuhan Optics Valley,…
Read More...